The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology
Clinical pharmacy services (CPS) have shown beneficial effects on several outcome measures in hospital patients, including the reduction of drug-related problems (DRP) and of therapy costs. Less is known about the impact of CPS in pediatric haemato-oncology, even though this patient population is hi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Children |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9067/9/4/479 |
| _version_ | 1797436309850030080 |
|---|---|
| author | Christina Gradwohl Gernot Engstler Martina Anditsch Herbert Pichler Gunar Stemer |
| author_facet | Christina Gradwohl Gernot Engstler Martina Anditsch Herbert Pichler Gunar Stemer |
| author_sort | Christina Gradwohl |
| collection | DOAJ |
| description | Clinical pharmacy services (CPS) have shown beneficial effects on several outcome measures in hospital patients, including the reduction of drug-related problems (DRP) and of therapy costs. Less is known about the impact of CPS in pediatric haemato-oncology, even though this patient population is highly susceptible to DRP. CPS were implemented in a tertiary care children’s hospital specialized in hemato-oncology and hematopoietic stem cell transplantation. The main outcome measures were type and number of DRP, type and number of pharmaceutical interventions (PI), their acceptance rate, and their clinical significance and economic benefit. During 6 months and 32 ward rounds, 275 DRP were identified and addressed by PI. The acceptance of PI was high (73.4%), and up to 80% of PI were rated as very significant or significant by independent external raters. The estimated therapy cost reductions were substantial, approaching at least EUR 54,600 for avoided follow-up costs. Conclusion: CPS improve medication safety in pediatric hemato-oncology and may reduce therapy costs. |
| first_indexed | 2024-03-09T11:00:46Z |
| format | Article |
| id | doaj.art-041e4a1e19e740ba93c595f59b9fe34e |
| institution | Directory Open Access Journal |
| issn | 2227-9067 |
| language | English |
| last_indexed | 2024-03-09T11:00:46Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Children |
| spelling | doaj.art-041e4a1e19e740ba93c595f59b9fe34e2023-12-01T01:17:52ZengMDPI AGChildren2227-90672022-03-019447910.3390/children9040479The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-OncologyChristina Gradwohl0Gernot Engstler1Martina Anditsch2Herbert Pichler3Gunar Stemer4St. Anna Children’s Hospital, Department of Paediatrics, Medical University of Vienna, 1090 Vienna, AustriaSt. Anna Children’s Hospital, Department of Paediatrics, Medical University of Vienna, 1090 Vienna, AustriaPharmacy Department, University Hospital AKH, 1090 Vienna, AustriaSt. Anna Children’s Hospital, Department of Paediatrics, Medical University of Vienna, 1090 Vienna, AustriaPharmacy Department, University Hospital AKH, 1090 Vienna, AustriaClinical pharmacy services (CPS) have shown beneficial effects on several outcome measures in hospital patients, including the reduction of drug-related problems (DRP) and of therapy costs. Less is known about the impact of CPS in pediatric haemato-oncology, even though this patient population is highly susceptible to DRP. CPS were implemented in a tertiary care children’s hospital specialized in hemato-oncology and hematopoietic stem cell transplantation. The main outcome measures were type and number of DRP, type and number of pharmaceutical interventions (PI), their acceptance rate, and their clinical significance and economic benefit. During 6 months and 32 ward rounds, 275 DRP were identified and addressed by PI. The acceptance of PI was high (73.4%), and up to 80% of PI were rated as very significant or significant by independent external raters. The estimated therapy cost reductions were substantial, approaching at least EUR 54,600 for avoided follow-up costs. Conclusion: CPS improve medication safety in pediatric hemato-oncology and may reduce therapy costs.https://www.mdpi.com/2227-9067/9/4/479pediatricshematopoietic stem cell transplantationhematologyoncologyclinical pharmacy servicesdrug-related problems |
| spellingShingle | Christina Gradwohl Gernot Engstler Martina Anditsch Herbert Pichler Gunar Stemer The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology Children pediatrics hematopoietic stem cell transplantation hematology oncology clinical pharmacy services drug-related problems |
| title | The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology |
| title_full | The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology |
| title_fullStr | The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology |
| title_full_unstemmed | The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology |
| title_short | The Impact of Clinical Pharmacy Services in a Tertiary Care Center Specialized in Pediatric Hemato-Oncology |
| title_sort | impact of clinical pharmacy services in a tertiary care center specialized in pediatric hemato oncology |
| topic | pediatrics hematopoietic stem cell transplantation hematology oncology clinical pharmacy services drug-related problems |
| url | https://www.mdpi.com/2227-9067/9/4/479 |
| work_keys_str_mv | AT christinagradwohl theimpactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT gernotengstler theimpactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT martinaanditsch theimpactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT herbertpichler theimpactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT gunarstemer theimpactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT christinagradwohl impactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT gernotengstler impactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT martinaanditsch impactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT herbertpichler impactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology AT gunarstemer impactofclinicalpharmacyservicesinatertiarycarecenterspecializedinpediatrichematooncology |